Cannabis law

WeedMD Inc. Announces $15 Million Bought Deal Equity Financing

Retrieved on: 
Thursday, February 11, 2021
Equity securities, Options, Cannabis, Cannabis law, Drug control law, Warrant, Starseed, Legality of cannabis

Each Unit will be comprised of one common share of the Company (a Common Share) and one-half of oneCommon Share purchase warrant (each whole warrant, Warrant).

Key Points: 
  • Each Unit will be comprised of one common share of the Company (a Common Share) and one-half of oneCommon Share purchase warrant (each whole warrant, Warrant).
  • The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes.
  • WeedMD Inc. is the publicly traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets.
  • With the addition of Starseed, a medical-centric operator, WeedMD has expanded its multi-channeled distribution strategy.

Tilray® Announces Agreement with Grow Pharma to Import and Distribute Medical Cannabis Products in the United Kingdom

Retrieved on: 
Tuesday, February 9, 2021
Alternative medicine, Health, Other Science, General Health, Research, Science, Pharmaceutical, Herbalism, Medicinal plants, Tilray, Health sciences, Branches of biology, Pharmaceuticals policy, Cannabis, Cannabis law, Legality of cannabis, Medical cannabis, Privateer Holdings

Tilray Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has established an agreement with Grow Pharma to import and distribute Tilrays medical cannabis products into the United Kingdom (UK).

Key Points: 
  • Tilray Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has established an agreement with Grow Pharma to import and distribute Tilrays medical cannabis products into the United Kingdom (UK).
  • This agreement allows Tilray to provide authorized UK patients in need with a locally maintained supply of medical cannabis solutions.
  • Tilray expects to have a range of GMP-certified, medical cannabis products available for patients in the UK by March 2021.
  • Grow Group PLC exists to unlock the medical potential of cannabis for those who need it though three business units: Grow Pharma, Grow Trading and Grow Biotech.

Green Life Business Continues To Lead The Cannabis Industry

Retrieved on: 
Tuesday, February 9, 2021
Articles, Cannabis law, Business, Drug control law, Psychoactive drugs, Medicinal plants, Cannabis, Green rush, Entrepreneurship, Legality of cannabis, Cannabis in Australia, Cannabis in Canada

Green Life Business Group Inc. is leading the cannabis business brokerage market Nationwide and has the numbers to back it up.

Key Points: 
  • Green Life Business Group Inc. is leading the cannabis business brokerage market Nationwide and has the numbers to back it up.
  • When it comes to finding a cannabis business for sale, California has no shortage of options.
  • Green Life conducts market research to identify the best businesses for sale to provide to entrepreneurs looking to get in on the Green Rush.
  • Green Life has sold 12 Cannabis businesses in the last 90 days.

GREENWERKS LLC Acquires New Assets, Licensed Cannabis Businesses, Multiple Revolutionary Technologies; Announces U.S First Nation Projects, Healing Centers and Global Expansions

Retrieved on: 
Wednesday, February 3, 2021
Herbalism, Medicinal plants, Health sciences, Branches of biology, Cannabis law, Drug control law, Legality of cannabis, Medical cannabis, Cannabis, Pharmaceutical sciences

During 1st Quarter 2020, GREENWAVE BUSINESS CONSULTANTS LLC developed products that unlock dormant capacities of the body and mind.

Key Points: 
  • During 1st Quarter 2020, GREENWAVE BUSINESS CONSULTANTS LLC developed products that unlock dormant capacities of the body and mind.
  • In 2021, GREENWERKS is acquiring more land, property, cannabis licenses, and cannabis businesses in California, Florida, Oregon, Oklahoma, and New Jersey.
  • Utilizing advanced modern and ancient natural medicines, GREENWERKS's healing resort centers will combat a broad spectrum of mental and physical illnesses.
  • Thanks to recent acquisitions and international expansions, GREENWERKS LLC is well-positioned and prepared for massive growth in 2021.

ManifestSeven Opens Scaled Multi-Purpose Facility in San Francisco Bay Area

Retrieved on: 
Tuesday, February 2, 2021
Health sciences, Cannabis, Cannabis law, Drug control law, M7, Medical cannabis, Legality of cannabis, Pharmaceutical sciences, Branches of biology

The Brisbane facility marks a significant strategic milestone for M7 as it progresses the statewide expansion of the Company's core regulated cannabis operations.

Key Points: 
  • The Brisbane facility marks a significant strategic milestone for M7 as it progresses the statewide expansion of the Company's core regulated cannabis operations.
  • The Brisbane facility is M7's largest distribution center to date and significantly expands the Company's operational capabilities and logistical efficiency in the region.
  • ManifestSeven is the first integrated omnichannel platform for legal cannabis, merging compliant distribution with a retail superhighway.
  • M7, headquartered in Irvine, California, services the needs of lawful operators across the supply chain, from the cultivator to the consumer, through an expansive network of four facilities stretching from the San Francisco Bay Area to San Diego.

Tilray® Receives the First and Only Market Authorization to Offer Medical Cannabis Products in Portugal

Retrieved on: 
Monday, February 1, 2021
Alternative medicine, Health, Other Science, Research, Pharmaceutical, Science, Medicinal plants, Entheogens, Euphoriants, Herbalism, Cannabis, Health sciences, Tilray, Psychoactive drugs, Cannabis law, Legality of cannabis, Medical cannabis, Privateer Holdings

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that it has received the necessary approvals and market authorization in accordance with the Portuguese legislation to offer Tilray medical cannabis products in Portugal from its GMP-certified EU facility in Cantanhede, Portugal.

Key Points: 
  • Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that it has received the necessary approvals and market authorization in accordance with the Portuguese legislation to offer Tilray medical cannabis products in Portugal from its GMP-certified EU facility in Cantanhede, Portugal.
  • Sascha Mielcarek, Tilray's Managing Director in Europe, says, "We are very proud of Infarmed's market authorization, which confirms Tilrays medical cannabis products live up to the highest national and international quality standards.
  • He continued, Patient demands are increasing in Portugal and throughout Europe, and our objectives are to provide them with the safest and best quality medical cannabis products.
  • The complete GMP-certification allows Tilray to manufacture medical cannabis extracts in-house and export GMP-produced finished medical cannabis products, both dried flower, and oil, from Portugal throughout the European Union and other international markets with authorized national medical cannabis programs.

NETA Awards $25,000 Security Equipment Grant to Social Equity Applicant Cannabis Delivery Service in Massachusetts

Retrieved on: 
Tuesday, January 26, 2021
Herbalism, Medicinal plants, Health sciences, Cannabis smoking, Branches of biology, Cannabis law, Psychoactive drugs, Medical cannabis, Legality of cannabis, Cannabis

FRANKLIN, Mass., Jan. 26, 2021 /PRNewswire/ -- New England Treatment Access (NETA), a division of the privately-held, multi-state cannabis company Parallel and a leading cannabis operator in Massachusetts, today announced that "Florencia," a social equity cannabis license applicant, is the recipient of $25,000 through its Security Equipment Grant Program.

Key Points: 
  • FRANKLIN, Mass., Jan. 26, 2021 /PRNewswire/ -- New England Treatment Access (NETA), a division of the privately-held, multi-state cannabis company Parallel and a leading cannabis operator in Massachusetts, today announced that "Florencia," a social equity cannabis license applicant, is the recipient of $25,000 through its Security Equipment Grant Program.
  • NETA's initiative is designed to help reduce barriers to entry for social equity applicants into the state's cannabis industry.
  • Florencia will be one of the first to receive a home-delivery license from the Cannabis Control Commission (CCC) for social equity applicants.
  • The $25,000 grant will be used to outfit their delivery vehicles with compliant security equipment, as mandated by the CCC.

Subversive Announces Qualifying Transaction with InterCure, Israel's Leading and Fastest-Growing Cannabis Company

Retrieved on: 
Tuesday, January 26, 2021
Cannabis, Cannabis law, Entheogens, Psychoactive drugs, Cannabis industry, Legality of cannabis, Branches of biology, Medicinal plants

Michael Auerbach, Founder of Subversive Capital, said, "We are excited to announce today's qualifying transaction, which, upon closing, will allow our shareholders to participate in the upside of the Israeli cannabis market.

Key Points: 
  • Michael Auerbach, Founder of Subversive Capital, said, "We are excited to announce today's qualifying transaction, which, upon closing, will allow our shareholders to participate in the upside of the Israeli cannabis market.
  • As we discover the scientific advantages in cannabis alongside new favorable legislation, the cannabis industry is unleashing its disruptive commercial potential.
  • Israel became famous for its breakthroughs in cannabis research and has now become one of the leading medical cannabis markets in the world.
  • Canndoc's Chief Executive Officer, Alex Rabinovitch, added,"We are thrilled to be partnering with Subversive Capital in this transaction.

Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France

Retrieved on: 
Tuesday, January 26, 2021
Science, Other Science, Research, Natural Resources, Pharmaceutical, Alternative medicine, Health, Other Natural Resources, Herbalism, Medicinal plants, Health sciences, Cannabis, Health care, Tilray, Pharmaceuticals policy, Cannabis law, Agence Nationale de Sécurité du Médicament et des Produits de Santé, Medical cannabis, Legality of cannabis, Privateer Holdings

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France.

Key Points: 
  • Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France.
  • Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021.
  • Tilray has received the necessary regulatory approvals to participate in the ANSM experimentation in France and will export medical cannabis products from its GMP-certified facility in Cantanhede, Portugal.
  • We are proud to be able to offer access to a variety of high-quality, pharmaceutical-grade medical cannabis products to the ANSM while supporting patients in need in France.

Greater Cannabis Company Announces Retirement of Remaining Convertible Debt

Retrieved on: 
Wednesday, January 20, 2021
Herbalism, Medicinal plants, Health sciences, Drug control law, Cannabis smoking, Branches of biology, Cannabis law, Cannabis, Psychoactive drugs, Medical cannabis, Legality of cannabis, Cannabis in Australia

The Greater Cannabis Company ( GCAN ) is a fully reporting publicly traded biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.

Key Points: 
  • The Greater Cannabis Company ( GCAN ) is a fully reporting publicly traded biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.
  • Greater Cannabis deploys its technology platform for use in the cannabis industry.
  • Greater Cannabis mission is to bring our technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers.
  • More information on the Greater Cannabis Company and its technology can be found on the Companys website, www.gcanrx.com .